Heritage Investors Management Corp Raises Position in IQVIA Holdings Inc. (NYSE:IQV)

Heritage Investors Management Corp grew its position in IQVIA Holdings Inc. (NYSE:IQVFree Report) by 9.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 87,744 shares of the medical research company’s stock after purchasing an additional 7,696 shares during the period. Heritage Investors Management Corp’s holdings in IQVIA were worth $17,243,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. FMR LLC raised its holdings in shares of IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after buying an additional 804,963 shares during the period. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in IQVIA during the 3rd quarter valued at approximately $147,683,000. JPMorgan Chase & Co. increased its holdings in IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares during the last quarter. Nordea Investment Management AB raised its position in shares of IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after purchasing an additional 452,029 shares in the last quarter. Finally, KBC Group NV boosted its stake in shares of IQVIA by 68.5% during the 4th quarter. KBC Group NV now owns 616,299 shares of the medical research company’s stock valued at $121,109,000 after buying an additional 250,458 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Stifel Nicolaus decreased their price objective on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a report on Friday, February 7th. BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Bank of America cut their price objective on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Truist Financial reiterated a “buy” rating and issued a $263.00 target price (up previously from $261.00) on shares of IQVIA in a research report on Monday, February 10th. Finally, Deutsche Bank Aktiengesellschaft lowered their price target on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $251.22.

Get Our Latest Research Report on IQVIA

Insider Transactions at IQVIA

In related news, Director John G. Danhakl acquired 1,275 shares of IQVIA stock in a transaction that occurred on Tuesday, December 3rd. The stock was acquired at an average price of $200.58 per share, with a total value of $255,739.50. Following the completion of the acquisition, the director now directly owns 1,275 shares of the company’s stock, valued at $255,739.50. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.60% of the company’s stock.

IQVIA Trading Down 0.1 %

IQVIA stock opened at $190.77 on Thursday. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a market capitalization of $33.59 billion, a price-to-earnings ratio of 25.44, a PEG ratio of 1.99 and a beta of 1.48. The firm has a 50-day moving average price of $199.40 and a two-hundred day moving average price of $215.46.

IQVIA (NYSE:IQVGet Free Report) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Profile

(Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Recommended Stories

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQVFree Report).

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.